Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP3K5 | Q99683 | 12/20 | 0.67 |
| ▸ | CSNK1D | P48730 | 4/20 | 0.55 |
| ▸ | CSNK1E | P49674 | 4/20 | 0.55 |
| ▸ | LMNA | P02545 | 1/20 | 0.54 |
| ▸ | RET | P07949 | 1/20 | 0.48 |
| ▸ | CDK2 | P24941 | 1/20 | 0.48 |
| ▸ | GSK3B | P49841 | 1/20 | 0.48 |
| ▸ | ITK | Q08881 | 1/20 | 0.48 |
| ▸ | MERTK | Q12866 | 1/20 | 0.48 |
| ▸ | PRKAA1 | Q13131 | 1/20 | 0.48 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3485613 | 0.91 | MAP3K5 (0.70) | MAP3K5CSNK1DCSNK1E | |
| SCHEMBL13498806 | 0.89 | MAP3K5 (0.57) | MAP3K5CSNK1DCSNK1E | |
| SCHEMBL13498813 | 0.88 | MAP3K5 (0.56) | MAP3K5CSNK1DCSNK1EMAPT | |
| SCHEMBL13498810 | 0.88 | MAP3K5 (0.56) | MAP3K5CSNK1DCSNK1E | |
| SCHEMBL13498815 | 0.88 | MAP3K5 (0.56) | MAP3K5CSNK1DCSNK1ERETCDK2 | |
| SCHEMBL13498805 | 0.88 | MAP3K5 (0.56) | MAP3K5CSNK1DCSNK1E | |
| SCHEMBL13498812 | 0.87 | MAP3K5 (0.55) | MAP3K5CSNK1DCSNK1E | |
| SCHEMBL13498814 | 0.87 | MAP3K5 (0.55) | MAP3K5CSNK1DCSNK1E | |
| SCHEMBL13498808 | 0.87 | MAP3K5 (0.55) | MAP3K5POLB | |
| SCHEMBL13498870 | 0.86 | MAP3K5 (0.56) | MAP3K5CSNK1DCSNK1ELMNARET |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100029619-A1 | FUSED HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMTED (JP) | 2010-02-04 | — | — | US | disclosed |
| US-20100029619-A1 | FUSED HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMTED (JP) | 2010-02-04 | — | — | US | disclosed |
| US-20100029619-A1 | FUSED HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMTED (JP) | 2010-02-04 | — | — | US | disclosed |
| EP-2058309-A1 | FUSED HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2009-05-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100029619-A1 | FUSED HETEROCYCLIC COMPOUND | IRAK1, IL1R1, IRAK2 | MAP3K5 42/4885CSNK1D 666/4885CSNK1E 772/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.